Results 111 to 120 of about 1,176,948 (213)
Layoutgetreues Digitalisat der Ausg.: Marburg, 1918 Standort: Zentralbibliothek Signatur: VIII C 1167 m ...
Universität [Marburg]
core +1 more source
A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease
Marburg virus disease (MVD) is a severe infectious disease caused by the Marburg virus (MARV), posing a significant threat to humans. MARV needs to be operated under strict biosafety Level 4 (BSL-4) laboratory conditions.
Wanying Yang +10 more
doaj +1 more source
Soni S, Rathish B.
europepmc +2 more sources
Verzeichnis der Vorlesungen / Philipps-Universität Marburg. SS 1858 – WS 1858/59
Layoutgetreues Digitalisat der Ausg.: Marburg, 1858 Standort: Zentralbibliothek Signatur: VIII C 1167 m ...
Universität [Marburg]
core +1 more source
Verzeichnis der Vorlesungen / Philipps-Universität Marburg. SS 1881 – WS 1881/82
Layoutgetreues Digitalisat der Ausg.: Marburg, 1881 Standort: Zentralbibliothek Signatur: VIII C 1167 m ...
Universität [Marburg]
core +1 more source
Marburg virus, a member of the Filoviridae, is the causative agent of Marburg virus disease (MVD), a hemorrhagic fever with a case fatality rate of up to 90 %.
Benjamin Koch +8 more
doaj +1 more source
Verzeichnis der Vorlesungen / Philipps-Universität Marburg. SS 1900 – WS 1900/1901
Layoutgetreues Digitalisat der Ausg.: Marburg, 1900 Standort: Zentralbibliothek Signatur: VIII C 1167 m ...
Universität [Marburg]
core +1 more source
Verzeichnis der Vorlesungen auf der Universität zu Marburg. SS 1802 - WS 1802/03
Layoutgetreues Digitalisat der Ausg.: Marburg, 1802 Standort: Zentralbibliothek Signatur: VIII C 1167 m ...
Universität [Marburg]
core +1 more source
Abstracts of 14th International Symposium on Hodgkin Lymphoma
HemaSphere, Volume 10, Issue S2, October 2026.
wiley +1 more source
The September 2024 outbreak of Marburg virus disease (MVD) represented the first time this virus was identified in Rwanda. Health authorities mounted a rapid and effective response, including the rapid execution of an open-label Phase 2 clinical trial of
Sabin Nsanzimana +18 more
doaj +1 more source

